Figure 3. Survival of patients with metastatic germ cell tumors stratified by existence of metastases to liver, brain and/or bone (LBB), platinum refractory disease, and transplantation in first vs. further relapse.

(A) Median progression free survival (mPFS) after high-dose chemotherapy (HDCT)/autologous stem cell transplantation (ASCT) stratified by LBB metastases differed significantly (log rank p = 0.011). (B) Median PFS after HDCT/ASCT differed significantly between patients with platinum responsive or refractory disease at time of HDCT/ASCT (log rank p = 0.008). (C) Transplantation upfront or in first relapse vs. second or higher relapse was neither significant for mPFS (10.8 months vs. 5.9 months; p = 0.41 Figure 3C) or mOS (not reached vs. 13.0 months; p = 0.21).